Rutgeerts P
Department of Internal Medicine, University Hospital of Leuven, Gasthuisberg, Belgium.
Neth J Med. 1994 Aug;45(2):60-4.
Crohn's recurrence is the appearance of objective signs--defined radiologically, endoscopically or pathologically--of Crohn's disease in the bowel of a patient who has previously had a resection of all macroscopically diseased tissue. New lesions can be visualized endoscopically within weeks to months after ileal resection and ileocolonic anastomosis in the neoterminal ileum. The evolution of these lesions mimics the natural history of ileal Crohn's disease at the onset. If we are able to prevent recurrence of early lesions, we could probably interrupt the natural course of the disease. Metronidazole decreases the severity of early recurrence without totally preventing it. The data on 5-ASA are conflicting. Claversal seems to have little effect whereas Asacol was found to prevent not only endoscopic but also clinical recurrence. Pentasa prevented the development of severe recurrence. New therapies including topically acting glucocorticosteroids and immune suppression should be studied.
克罗恩病复发是指在先前已切除所有肉眼可见病变组织的患者肠道中,出现经放射学、内镜或病理学定义的克罗恩病客观体征。在回肠切除和回结肠吻合术后数周数月内,新病变可在内镜下于新末端回肠中显现。这些病变的演变在发病时模仿回肠克罗恩病的自然病程。如果我们能够预防早期病变的复发,或许就能阻断疾病的自然进程。甲硝唑可减轻早期复发的严重程度,但不能完全预防。关于5-氨基水杨酸(5-ASA)的数据存在矛盾。克拉维沙似乎效果甚微,而美沙拉嗪不仅能预防内镜复发,还能预防临床复发。颇得斯安可预防严重复发的发生。应研究包括局部作用的糖皮质激素和免疫抑制在内的新疗法。